Credit Suisse analyst Richard Law maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Neutral and lowers the price target from $90 to $78.
Famed Short-Seller Jim Chanos Reveals Short Position On GE — Says This Bitcoin-Linked Stock Is ‘Narrative,’ Not ‘Fundamental’
Famed short-seller Jim Chanos revealed his short position on General Electric Company (NYSE: GE) shares, saying that the company’s fair value was "way below" its current stock price, according to a Reuters report that cited a CNBC interview.
